Key Takeaway: Hengrui Pharma and Kailera Therapeutics presented clinical data on ribupatide, a dual agonist targeting GLP-1 and GIP receptors, at ADA 2026. The drug is being developed in both a once-weekly injection and a once-daily oral form for obesity treatment. Phase 2 trial results for the oral formulation were highlighted, showing positive outcomes.
Price reaction · baseline $19.37 (2026-06-05 close) · hit after-hours · clean, no other KLRA news in the window
day 0 close · peak
+1.7%
Market Sentiment Analysis
POSITIVE FACTORS
Ribupatide shows promising clinical results for obesity treatment.
Dual agonist mechanism may enhance efficacy in weight management.
Data presented at ADA 2026 highlights innovative delivery methods.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+2%
120-day peak, hindsight
Typical move
2%
average across 2 past catalysts
Cash runway
~44 mo
Minimal dilution risk
Lead asset
Ribupatide (KAI-9531)
Phase 3 · Obesity
Full Press Release Details
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean
Frequently Asked Questions
What is ribupatide?
Ribupatide is a dual agonist targeting GLP-1 and GIP receptors for obesity treatment.
What forms of ribupatide are being developed?
Ribupatide is being developed as a once-weekly injection and a once-daily oral pill.
Where was the ribupatide data presented?
The clinical data for ribupatide was presented at ADA 2026.
What were the results of the Phase 2 trial?
The Phase 2 trial of ribupatide oral demonstrated positive clinical outcomes.